Related Experiment Video
Updated: Aug 2, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
MicroRNA-27a Suppresses the Toxic Action of Mepivacaine on Breast Cancer Cells via Inositol-Requiring Enzyme 1-TNF
WenHong Fu1, XiaoLing Hu2, GengZhang Li1
1Department of Anesthesiology, Nanhua Hospital Affiliated to Nanhua University, ShaoYang 422001, Hunan Province, China.
Objective:
To investigate the toxic effects of microRNA-27a on breast cancer cells through inositol-acquiring enzyme 1-TNF receptor-associated factor 2 inhibition by mepivacaine.
Methods:
The elevation of miR-27a in MCF-7 of BCC lines was measured, and groups were set up as control, mepivacaine, and elevated groups. Cells from each group were examined for inflammatory progression.
Results:
Elevated miR-27a in MCF-7 cells was able to distinctly augment the cell advancement (P < 0.01) and decline cell progression (P < 0.01). Meanwhile, miR-27a reduced the content of intracellular inflammatory factors IL-1β (P < 0.01) and IL-6 (P < 0.01), elevated the content of IL-10 (P < 0.01), suppressed levels of cleaved-caspase-3 and p-signal transducer and activator of transcription-3 (STAT3) (P < 0.01), and increased Bcl-2/Bax (P < 0.01).
Conclusion:
Elevated miR-27a in MCF-7 of BCC lineage was effective in reducing the toxic effects of mepivacaine on cells and enhancing cell progression. This mechanism is thought to be related to the activation of the IRE1-TRAF2 signaling pathway in BCC. The findings may provide a theoretical basis for targeted treatment of BC in clinical practice.
Insights
MicroRNA-27a (miR-27a) enhances breast cancer cell progression and reduces inflammation by inhibiting IL-1β and IL-6. Elevated miR-27a counteracts mepivacaine
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
- Dysregulation of miR-27a has been implicated in various cancers, including breast cancer.
- Mepivacaine's effects on cancer cells and its interaction with miRNAs are not fully understood.
Purpose of the Study:
- To investigate the toxic effects of microRNA-27a on breast cancer cells.
- To explore the role of miR-27a in inhibiting the inositol-acquiring enzyme 1-TNF receptor-associated factor 2 (IRE1-TRAF2) pathway.
- To determine the impact of mepivacaine on miR-27a expression and breast cancer cell behavior.
Main Methods:
- MCF-7 breast cancer cells were used to measure miR-27a levels.
- Cells were divided into control, mepivacaine-treated, and miR-27a-elevated groups.
- Inflammatory markers, cell proliferation, apoptosis, and signaling pathway activation were assessed.
Main Results:
- Elevated miR-27a significantly augmented MCF-7 cell advancement and decreased cell progression.
- miR-27a reduced pro-inflammatory cytokines (IL-1β, IL-6) and increased anti-inflammatory cytokine (IL-10).
- miR-27a suppressed cleaved-caspase-3 and p-STAT3, increased Bcl-2/Bax ratio, indicating anti-apoptotic effects.
Conclusions:
- Elevated miR-27a reduces mepivacaine's toxic effects on breast cancer cells and enhances cell progression.
- The mechanism involves the activation of the IRE1-TRAF2 signaling pathway.
- Findings suggest miR-27a as a potential therapeutic target for breast cancer treatment.
Related Concept Videos
01:22MicroRNAs
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...